Dr. Rohlff received his Ph.D. from the Department of Pharmacology at Georgetown University in 1994. After two appointments at the National Cancer Institute he joined Oxford GlycoSciences and was appointed Director of Proteome Research Collaborations in 2001. As manager of the Proteomics Division's commercial collaborations he gained expertise in the implementation of clinical proteomics programmes to identify novel therapeutic protein targets and protein biomarkers with many pharmaceutical companies and academic partners, including Pfizer, GSK, Bayer, Wyeth, Takeda, the Cystic Fibrosis Foundation, Oxford University and the FDA. These studies have investigated many disease areas including Alzheimer's disease, arteriosclerosis, dermal ulcers, asthma, chronic obstructive pulmonary disease, various metabolic, inflammatory and neuropsychiatric disorders, toxicology, and oncology. Dr Rohlff co-authored over 20 protein patents originating from these studies. Dr. Rohlff is the founder of Oxford BioTherapeutics.

Jim Cornett received his PhD in molecular biology at the University of Arizona Medical School and completed post-doctoral studies at Temple University Medical School in Philadelphia. In 1978, Jim joined Sterling Drug and led basic research and project teams for new antimicrobial agents from research through the IND stage of development. In 1986 Jim joined the clinical research department at Centocor as an Assistant Director, beginning a more than twenty year career with monoclonal antibodies as therapeutic agents. While at Centocor, Jim contributed to multiple areas including clinical research, regulatory affairs, project management and technology transfer to commercial partners in Japan. Jim joined Protein Design Labs in 1993 as Director of Business Development where he focused on global licensing of antibody-related technologies including antibody humanization. In 2000, he joined his third antibody company, Medarex, as Vice President, Business Development. His work led to the establishment of numerous licensing and collaborative R&D relationships in the area of fully human antibody therapeutics with both biotech and global pharmaceutical companies. In addition to his role as COO, Jim is President of the company’s US subsidiary, Oxford BioTherapeutics Inc.

Jon Terrett completed his PhD and postdoctoral work in human genetics at Nottingham in 1996 after which he moved to Smithkline Beecham to establish the pharmacogenetics and DNA microarray laboratories. In 1999 he moved to Oxford Glycosciences (OGS) as Director of Molecular Oncology and spent the next 5 years building the Oncology MAb target discovery program. This platform fed multiple antibody companies with targets, the most successful collaboration being with Medarex where many lead drug candidates were selected and tested in vivo. Following Celltech’s acquisition of OGS, Dr Terrett moved to Medarex (USA) in 2004 to complete the work developing the drugs discovered via the proteomics platform and progressed two into phase1 clinical trials and many others through preclinical proof of concept. Jon is based at the company’s US subsidiary, near San Jose, CA.

Mike Gresser received his Ph.D in Biochemistry in 1976 and after postdoctoral studies at the Molecular Biology Institute at UCLA he joined the Department of Chemistry at Simon Fraser University in Burnaby, British Columbia. In 1988 Mike Joined the Merck Frosst Center for Therapeutic Research in Kirkland, Quebec as Director of Biochemistry. Over the next twelve years Mike progressed to Executive Director of Biochemistry and Molecular Biology and his team worked on a variety of small molecule drug discovery programs, resulting in the introduction of numerous molecules into clinical trials. Two of these molecules, Singulair and Vioxx, became products. In 2000 Mike joined Amgen Inc. in Thousand Oaks, California, as Vice President Research for Inflammation, where he remained until April, 2006. Mike’s team at Amgen worked on many molecular targets, introducing numerous small molecules, human antibodies, and other proteins into development. Currently Mike is also Visiting Scholar at the Molecular Biology Institute at UCLA.

Tom is an experienced bench scientist and manager having served a 28 year career with Amgen. Tom started as a research associate cDNA cloning and sequencing genes including G-CSF (Neupogen). During the late 80’s and throughout the 1990’s Tom worked in process development as a scientist and director and developed or oversaw the development of many of the processes implemented at Amgen including the Neupogen process.
Tom headed the expression, purification, and characterization groups within Amgen's research group which went on to become the Protein Science group. Over the years other support research groups and protein science groups from other sites have been added and created.